Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: A randomized, placebo controlled trial for dose optimization in 128 healthy subjects
- 15 May 2006
- journal article
- research article
- Published by Elsevier BV in Vaccine
- Vol. 24 (20), 4343-4353
- https://doi.org/10.1016/j.vaccine.2006.03.009
Abstract
No abstract availableKeywords
This publication has 59 references indexed in Scilit:
- Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis CHepatology, 2005
- Regulatory T Cells Suppress In Vitro Proliferation of Virus-Specific CD8+T Cells during Persistent Hepatitis C Virus InfectionJournal of Virology, 2005
- Mutational escape from CD8+ T cell immunityThe Journal of Experimental Medicine, 2005
- Comparable functions of plasmacytoid and monocyte-derived dendritic cells in chronic hepatitis C patients and healthy donorsJournal of Hepatology, 2005
- Subversion of effector CD8+ T cell differentiation in acute hepatitis C virus infection: exploring the immunological mechanismsEuropean Journal of Immunology, 2004
- Novel CD4+ and CD8+ T-cell determinants within the NS3 protein in subjects with spontaneously resolved HCV infectionHepatology, 2003
- Conserved hepatitis C virus sequences are highly immunogenic for CD4+ T cells: Implications for vaccine developmentHepatology, 1999
- Epidemiology of hepatitis CHepatology, 1997
- Hepatitis C virusDigestive Diseases and Sciences, 1996
- Challenges for development of hepatitis C virus vaccinesFEMS Microbiology Reviews, 1994